Petvivo Hldgs Inc Stock Price, News & Analysis

PetVivo Holdings (NASDAQ: PETV) invites investors to its live presentation on September 29, 2021, at the Emerging Growth Conference. The event will feature CEO John Lai discussing the company's innovative medical therapeutics for pets, including their lead product, spryng™ with OsteoCushion™ Technology. Attendees will have the opportunity to ask questions directly during the session starting at 12:00 PM ET. For those unable to attend, an archived webcast will be available later.

PetVivo Holdings, Inc. (NASDAQ: PETV) announced the appointment of Josh Wilhelm as the new Director of Manufacturing. Wilhelm brings expertise in cGMP manufacturing and process engineering, previously serving at the Schulze Diabetes Institute. He aims to enhance the production of spryng, a therapeutic product for treating arthritis in companion animals. The company focuses on innovative medical devices for pets, with a pipeline of 17 products and 21 patents. spryng is expected to expand its commercial availability later this year.

PetVivo Holdings, Inc. (NASDAQ: PETV) announced Mark Middleton as the new National Director of Sales. His 38 years of experience in the Animal Health Industry, including leadership roles at Animal Health International, is expected to enhance sales of PetVivo's spryng™ product, which utilizes OsteoCushion Technology for treating osteoarthritis in pets. The company aims to accelerate revenue generation by leveraging innovative medical therapeutics for companion animals. The lead product is set for expanded commercial sale later this year.

PetVivo Holdings, Inc. (NASDAQ: PETV) will exhibit at the Western Veterinary Conference in Las Vegas from September 6-9, 2021. The company aims to showcase its lead product, SPRYNG^™ with OsteoCushion^™ Technology, designed for treating joint afflictions in pets. The conference is the largest veterinary event in the Western U.S., attracting over 15,000 participants. PetVivo CEO John Lai expressed optimism about forming industry connections to advance SPRYNG's development and commercialization, with broader sales expected in Q4.

PetVivo Holdings (NASDAQ: PETV) appoints Dr. Ann Zieser as Senior Technical Veterinarian, enhancing the company's veterinary expertise. Dr. Zieser brings over 31 years of experience in veterinary medicine, specializing in companion animal care. She aims to support the introduction of SPRYNG™, a treatment for osteoarthritis in pets, which is set for expanded commercial sales later this year. PetVivo focuses on innovative treatments for companion animals, leveraging human therapies for faster market entry.

PetVivo Holdings, Inc. (NASDAQ: PETV) has rebranded its therapeutic osteoarthritis product as “SPRYNG”. This change reflects the product's focus on enhancing mobility and quality of life for pets. SPRYNG utilizes OsteoCushion Technology, which supports joint health by replacing damaged cartilage and aiding tissue healing. The product is set for expanded commercial sales later this year and is backed by a robust pipeline of seventeen animal therapeutic products and twenty-one protective patents. CEO John Lai and Marketing Director Russ Siakel emphasize the life-changing benefits of SPRYNG for companion animals.

PetVivo Holdings, Inc. (NASDAQ: PETV) announced the appointment of Russell Siakel as the new Director of Marketing. Siakel, who has consulted for the Company since January 2021, brings over 30 years of experience in the animal health industry, previously working with Pfizer Animal Health and Boehringer Ingelheim. He aims to enhance the company's marketing efforts and product awareness. PetVivo focuses on innovative medical therapeutics for companion animals, with a portfolio of 17 products and 21 patents, including their lead product Kush, targeting osteoarthritis treatment in dogs and horses.

PetVivo Holdings, Inc. (NASDAQ: PETV) announces its participation in the Emerging Growth Conference on August 18, 2021, at 10:15 AM ET. This event will feature an interactive presentation by CEO John Lai, allowing investors to engage and ask questions in real time. PetVivo focuses on innovative medical therapeutics for pets, with a product pipeline including its lead offering, Kush, aimed at treating osteoarthritis in dogs and horses. An archived webcast will be available for those unable to attend live.

PetVivo Holdings closed its public offering of 2,500,000 units at $4.50 each, raising approximately $11.25 million. Each unit comprises one common stock share and a warrant to purchase one share at $5.625, exercisable immediately for five years. The offering, which included an over-allotment option of 375,000 warrants exercised by the underwriter, supports marketing, R&D, and debt repayment. The stock began trading on Nasdaq under the symbols PETV and PETVW on August 11, 2021.